Critical Outcome Technologies Inc. Announces COTI-2 Scientific Results Accepted for Presentation at Influential Scientific Conference

摘要

Critical Outcome Technologies Inc. (COTI) (TSX VENTURE:COT) announced that a scientific abstractnabout its lead oncology compound, COTI-2, has been accepted for presentation at the upcomingnscientific conference, Discovery on Target: Emerging Targets for the Kinase Inhibitor Pipeline. Thenpresentation entitled COTI-2: A highly effective and selective modulator of Akt/Akt2 protein levels andnphospho-activation for the treatment of susceptible human cancers will be presented by Dr. WaynenDanter, COTI's CEO and CSO. This conference is being held November 2-4, 2011 in Boston, MA.